Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Peter Hartung

Showing results (61-70 of 601) with videos related to

Pageof 61
Sort By:
Current Opinion in Neurology|April 27, 2011
Managing the risks of immunosuppressionD Sean Riminton, Hans-Peter Hartung, Stephen W Reddel
Annals of Neurology|April 27, 2011
The complex world of oligodendroglial differentiation inhibitorsDavid Kremer, Orhan Aktas, Hans-Peter Hartung, et al.
Current Neurology and Neuroscience Reports|April 15, 2003
New immunopathologic insights into multiple sclerosisBernhard Hemmer, Bernd Kieseier, Sabine Cepok, et al.
Trends in Neurosciences|March 12, 2016
Pushing Forward: Remyelination as the New Frontier in CNS DiseasesDavid Kremer, Peter Göttle, Hans-Peter Hartung, et al.
Current Opinion in Neurology|May 17, 2006
Central nervous system infections - a potential complication of systemic immunotherapyBernhard Hemmer, Eiliot Frohman, Hans Peter Hartung, et al.
Archives of Neurology|June 24, 2004
Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinasesBernd C Kieseier, Juan J Archelos, Hans-Peter Hartung
Expert Review of Clinical Pharmacology|November 14, 2012
Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosisOscar Fernandez, Thomas Berger, Hans-Peter Hartung, et al.
CNS Drugs|September 28, 2005
Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstaclesOliver Neuhaus, Olaf Stüve, Scott S Zamvil, et al.
Handbook of Clinical Neurology|February 11, 2014
Immune regulation of multiple sclerosisHans-Peter Hartung, Orhan Aktas, Til Menge, et al.
Neurology|April 27, 2005
Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationaleGeorge P A Rice, Hans-Peter Hartung, Peter A Calabresi
Pageof 61

Showing results (61-70 of 601) with videos related to

Sort By:
Pageof 61
Current Opinion in Neurology|April 27, 2011
Managing the risks of immunosuppressionD Sean Riminton, Hans-Peter Hartung, Stephen W Reddel
Annals of Neurology|April 27, 2011
The complex world of oligodendroglial differentiation inhibitorsDavid Kremer, Orhan Aktas, Hans-Peter Hartung, et al.
Current Neurology and Neuroscience Reports|April 15, 2003
New immunopathologic insights into multiple sclerosisBernhard Hemmer, Bernd Kieseier, Sabine Cepok, et al.
Trends in Neurosciences|March 12, 2016
Pushing Forward: Remyelination as the New Frontier in CNS DiseasesDavid Kremer, Peter Göttle, Hans-Peter Hartung, et al.
Current Opinion in Neurology|May 17, 2006
Central nervous system infections - a potential complication of systemic immunotherapyBernhard Hemmer, Eiliot Frohman, Hans Peter Hartung, et al.
Archives of Neurology|June 24, 2004
Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinasesBernd C Kieseier, Juan J Archelos, Hans-Peter Hartung
Expert Review of Clinical Pharmacology|November 14, 2012
Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosisOscar Fernandez, Thomas Berger, Hans-Peter Hartung, et al.
CNS Drugs|September 28, 2005
Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstaclesOliver Neuhaus, Olaf Stüve, Scott S Zamvil, et al.
Handbook of Clinical Neurology|February 11, 2014
Immune regulation of multiple sclerosisHans-Peter Hartung, Orhan Aktas, Til Menge, et al.
Neurology|April 27, 2005
Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationaleGeorge P A Rice, Hans-Peter Hartung, Peter A Calabresi
Pageof 61